lung cancer
Conditions
Interventions
Control group:chemotherapy
Experimental group:Immunochemotherapy
Sponsors
Second Hospital of Lanzhou University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 60 patients with advanced nonoperable or postoperative non-small cell lung cancer were confirmed by histopathology (stage ? - ? according to TNM of 8th edition of lung cancer); 2. ECOG (Eastern Oncology Collaboration) : 0 - 2 points; 3. 30 patients in the experimental group were treated with carrilizumab combined with chemotherapy, and 30 patients in the control group were treated with chemotherapy alone; 4. Patients aged 18-75 years, without systemic therapy, without immunotherapy, and without targeted therapy; 5. EGFR, ALK, ROS1 and other drive gene mutation negative; 6. Measurable lesions in compliance with RECIST 1.1; 7. Complete clinical data, hematological results and follow-up records; 8. No contraindications of chemotherapy were found in blood routine and biochemical indexes; 9. There were no abnormalities in thyroid function, cardiopulmonary function, adrenal function, liver and kidney function, and no contraindications of immunotherapy in the enrolled patients; 10. The informed consent has been signed with the consent of the applicant, with good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1. A history of other primary malignant tumors and chronic inflammatory diseases; 2. Expected survival <= 3 months; 3. Patients with obvious active brain metastases were excluded; 4. Patients with clinical evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-induced lung injury or severely impaired lung function; Patients with uncontrolled hypertension; 5. Known allergy, hypersensitivity or intolerance to carrelizumab; 6. The subject has a known history of psychotropic drug abuse, alcoholism or drug addiction; 7. Any conditions that the Investigator believes may impair the subject or cause the subject to fail to meet or perform study requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lymphocyte Subsets; | — |
Countries
China
Contacts
Public ContactLi Guixiang
Second Hospital of Lanzhou University
Outcome results
None listed